Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept studyJoseph J. Eron, Marina Caskey, Gordon Crofoot et al.|The Lancet HIV|2024Cited by 47